TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05689541

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile app intervention
Description: A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes.
Study: NCT06416449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotape application
Description: In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests.
Study: NCT05050682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is an anti-viral, formulated for intravenous delivery
Study: NCT05950659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orpyx Sensory Insole System
Description: The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
Study: NCT04702789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol-brimonidine and latanoprost
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol and latanoprost
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Study: NCT06132308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block with 0.25% bupivacaine
Description: Peng block was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with 0.25% bupivacaine
Description: Peng block was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with 0.25% bupivacaine
Description: Peng block was performed.
Study: NCT06566716

Intervention type: DIAGNOSTIC_TEST
Intervention: CleoDX ovarian cancer test
Description: A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.

Intervention type: DIAGNOSTIC_TEST
Intervention: CleoDX ovarian cancer test
Description: A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
Study: NCT05787483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindUP group
Description: MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: business as usual; regular wellness or SEL classes
Study: NCT05990465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells
Description: Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
Study: NCT05494736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth.
Study: NCT06362889

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microneedling with CBD
Description: Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
Study: NCT05535244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered by IV infusion in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered by IV infusion in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered by IV infusion in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered by IV infusion in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study: NCT06337097

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Troponin surveillance
Description: Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
Study: NCT05272579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Filtrate Transfer
Description: Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05546385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Rebreathing Device
Description: Partial Rebreathing Device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham breathing device
Description: Sham breathing device
Study: NCT06439927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycaprolactone nasal mesh
Description: a 3-dimensional fabricated Polycaprolactone nasal mesh
Study: NCT06425588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical/Procedure Mask Fit Testing
Description: All participants will wear a surgical/procedure mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KN95 Mask Fit testing
Description: All participants will wear a KN95 mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
Study: NCT05960929

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Infasurf Aero™
Description: A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Infasurf Aero™
Description: A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
Study: NCT05685160

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI with contrast
Description: MRI of the forefoot with contrast (Gadovist)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with contrast
Description: MRI of the forefoot with contrast (Gadovist)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound imaging of the forefoot

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging of the forefoot
Study: NCT06585423

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sterile commercially available bandage contact lens
Description: Medical grade acrylic tip covered by a sterile commercially available bandage contact lens

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade silicone of a thickness <100 µm
Description: Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade silicone of a thickness >100 µm
Description: Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
Study: NCT06580743

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study: NCT05394116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garetosmab
Description: Garetosmab is supplied as a liquid drug product and will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garetosmab
Description: Garetosmab is supplied as a liquid drug product and will be administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Study: NCT06356350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neuromuscular exercises
Description: Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core based exercises
Description: Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
Study: NCT04944017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infusion
Description: Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Saline Infusion
Description: Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
Study: NCT05284747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Lipid Management
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Lipid Management
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Study: NCT05936138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study: NCT05378425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-1088
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-1088
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-1088
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-1088
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study: NCT05832827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
Study: NCT04745858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's Technique
Description: In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique
Description: Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
Study: NCT05728983

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep levels
Description: Sleep levels are what the experimenter prescribes to participants in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep levels
Description: Sleep levels are what the experimenter prescribes to participants in the study.
Study: NCT04864977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Participants administered basal insulin
Study: NCT06585670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm Health - smartphone application
Description: Participants randomized to the intervention arm of the study will be given free access to a mobile phone application called Calm Health, which they will use to engage in guided meditation and mindfulness modules for at least 10 minutes per day for 8 weeks.
Study: NCT04525222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via text notifications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via text notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention (Actify app)
Description: Use Actify app
Study: NCT05832827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Study: NCT04525222

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (Current Standard Care app)
Description: Use (USCPG) Current Standard Care app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05493618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Study: NCT04864080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer game/task
Description: N-back, COGED, PacMan game, Bandit task, Websurf task.
Study: NCT06523387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Online (PRT-O) Course
Description: Pivotal Response Treatment - Parent Training
Study: NCT05528588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix
Description: Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix
Description: Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic Therapy
Description: Patients will receive home dose oral furosemide or oral furosemide per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic Therapy
Description: Patients will receive home dose oral furosemide or oral furosemide per standard of care.
Study: NCT06575595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
Study: NCT05997615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-500 (SAR446329)
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-500 (SAR446329)
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion